| Prev Close | 241.66 |
| Day Low/High | 240.02 / 246.84 |
| 52 Wk Low/High | 177.05 / 264.97 |
Amgen Inc. (AMGN)
245.49
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 582.17B |
| Market Cap | 140.69B |
| P/E Ratio | 19.16 |
| Div & Yield | N.A. (N.A) |
The Dow Binges on Earnings
Get ready for another heavy earnings slate
Intermediate Trade: QQQ
Try this bearishly biased, out-of-the-money put spread on the Nasdaq 100 ETF.
Intermediate Trade: QQQ
Consider this bearishly biased, August put spread.
With Solid Base, Amgen Keeps Climbing
The stock is set up well for more upside and remains very near a low-risk buy zone.
Intermediate Trade: QQQ
The tactic is the bearishly biased, calendar diagonal call spread, which controls the risk of the trade.
Takeaways and Observations
"Success breeds complacency. Complacency breeds failure. Only the paranoid survive." - Andy Grove  Perhaps this qualifies as a potential warning from "Uncle" Bob Farrell's ten lessons of investing.  Frankly, I thought dumping Ford's Fields was idi...
Wake Up Wall Street: Political Upheaval Surrounding President Trump Shows No Sign of Abating
Wake Up Wall Street: Political Upheaval Surrounding President Trump Shows No Sign of Abating
Closing Bell: PayPal Pushes Nasdaq to New Record; Crude Ends at One-Month Low
Better-than-expected earnings from PayPal drove the Nasdaq to new records, while a slump in crude oil kneecaps any big gains for the rest of the market.
Early-Morning Earnings Extravaganza
It is hard to keep up with the flurry of first-quarter earnings reports hitting the wires this morning. Here are a few that caught my eye today. Biotech stalwarts Amgen and Celgene posted mixed results, while AbbVie seems to have beat both top- and ...
Cramer: Nasdaq 6000 (the Number) vs. Nasdaq 2000 (the Year)
You think the exchange is overvalued? I don't, and here's why.
Jim Cramer on What's Next for Amgen Shares
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer sheds light on what's next for Amgen AMGN shares following its downgrade by Jefferies.
Cramer: 3 Health Care Bill Scenarios, 3 Game Plans
Get your plan in place, but understand that the Republic is not in jeopardy.
These 4 Healthcare Charts Are Signaling Buys
Here's a rundown of four technical setups that are showing solid trading potential.
Finding Bullish and Bearish Market Reversals
These stocks are showing signs of changing direction.
Closing Bell: Citi Dumps SeaWorld; U.S. Stocks Churn as Health Care Falls
Stocks churn around the flatline to end the week as a selloff in health care counters gains seen elsewhere.
Cramer: Nothing to See in This Market, Move Along
Today's session is reminiscent of a pre-Trump day.
Midday Report: Amgen Leads Health Care Lower; U.S. Stocks Fall
Stocks creep lower on Friday as a selloff in health care extends into its second day, this time led by Amgen shares.
Jim Cramer Discusses Adobe, Amgen, Canada Goose, Costco and Starbucks
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer discusses Friday's most talked about stocks including Adobe Systems, Amgen, Canada Goose, Costco and Starbucks.
Jim Cramer: I Don't Want to Give Up On Amgen
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer doesn't want to give up on Amgen.
Is Amgen's Cholesterol Drug Repatha Worth Its Hefty Price Tag?
Repatha costs $14,000 per year before discounts.
Cramer on What to Expect From Amgen's Investors Day Friday
'It'll still go higher.'
Cramer: The Airlines and Health-Care Names Are Really Soaring
This reversal has been incredible to watch.
Jim Cramer Previews the Fed Statement and Talks Apple, Oil, Amgen and MSCI
TheStreet's Jim Cramer discusses Wednesday's trending stocks.
Health Care Putting in a Base
Healthcare stocks had a heckuva four-year period of over-performance that ended in the summer of 2015. Since then the Health Care Select Sector SPDR ETF (40% pharma and 15% biotech) has had a series of trading-range moves as sector prices lagged. La...
Egalet Makes Friday's Biotech Mailbag
Why the name is sagging, and what it will take to spur the sector higher.
Cramer: When a Trump Tweet Is a Buy Signal
Drug companies are the latest targets/beneficiaries.
Jim Cramer on Donald Trump's Drug Tweet: "No One Really Knows What He Means"
Jim Cramer says no one really knows what President Trump means when it comes to drug pricing.
Drugmakers Suffer After Trump Tweet
Stocks were under pressure again after Donald Trump made vague promises to lower drug prices.
Amgen Is Making an Important Upside Breakout
The 50-day moving average is crossing the 200-day for a bullish golden cross; go long here.
